Incyte Corp (INCY) Q1 2021 Earnings Call Transcript

Incyte Corp (INCY) Q1 2021 Earnings Call Transcript
Motley Fool Transcribers, The Motley Fool
·48 min read

Last month, we presented updated data for RUX cream at the American Academy of Dermatology meeting, including the two-year data from our Phase 2 vitiligo trial and updated pooled results from our Phase 3 TRuE-AD program in atopic dermatitis with each highlighting the exciting potential of ruxolitinib cream as a treatment for these two indications. If approved baracitinib could be the first FDA approved therapy in alopecia areata.